AZD1656 is a potent, selective and orally active glucokinase activator with an EC 50 of 60 nM. AZD1656 has the potential for type 2 diabetes research In Vivo AZD1656 (0-9 mg/kg; oral gavage; daily; for 8 weeks; C57BL/6 mice) treatment shows lowered blood glucose and glucose excursion and raised insulin. Liver mRNA levels for various ChREBP target genes including carbohydrate response element binding protein beta isoform (ChREBP-β), G6pc, Pklr, Acly, Acac and Gpd2 are increased by AZD1656 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice Dosage: 0 mg/kg, 2 mg/kg, 4.5 mg/kg, 9 mg/kg Administration: Oral gavage; daily; for 8 weeks Result: Administered 2 hours before the oral glucose tolerance test, lowered blood glucose and glucose excursion and raised insulin. Form:Solid IC50& Target:EC50: 60 nM (Glucokinase)